top of page

The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.

ASX Announcements

1 September 2023    Cleansing Notice 

30 August 2023    Preliminary Final Report 

24 August 2023    Investor Presentation

28 July 2023

ASX Announcement. Read more.

28 July 2023

ASX Announcement. Read more

27 July 2023

20 July 2023

Shareholder newsletter. Read more.

30 June 2023

ASX Announcement. Read more.

30 June 2023

ASX Announcement. Read more.

6 June 2023

16 May 2023

BCAL appoints David Darling as an advisor. Read more.

11 May 2023

ASX Announcement. Read more. 

3 May 2023

ASX Announcement. Read more.

3 May 2023

16 Jan 2023

ASX Announcement. Read more

24 Apr 2023

ASX Announcement. Read more

7 Feb 2022

Recent Analysis Significantly Improves Commercial Prospects. Read more

25 October 2022

Establishment of Development & Clinical Services Laboratory. Read more

28 June 2022

BCAL Enters US Product Development Agreement with Precion. Read more

12 May 2022

BCAL Files Foundational Patent Application. Read more

24Mar 2022

Shareholder Newsletter. Read more

8 Feb 2022

7 February Announcement - Additional Information. Read more

15 Nov 2022

Shareholder Newsletter. Read more

BCAL Presentation Accepted for 2022 ASCO Annual Meeting. Read more

11 Jan 2022

3 Nov 2021

21 Oct 2021

3 Sep 2021

17 Aug 2021

22 July 2021

Dr John Hurrell Appointed Chief Executive Officer. Read more

Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test. Read more

Notice of Annual General Meeting and Explanatory Statement. Read more

Australian Clinical Studies Launched. Read more

Market Update. Read more

Becoming a substantial holder. Read more

21 July 2021

BCAL Diagnostics to list after raising $10m in IPO. Read more

bottom of page